Health Care Resource Use (HCRU) Due To Bleeding Related Episodes (BRE) In Patients With Immune Thrombocytopenic Purpura (ITP) Receiving Eltrombopag (EPAG), Romiplostim (ROMI), Or Rituximab (RITUX)- Real World Evidence (RWE) From 27 US Insti ...
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.903
https://www.valueinhealthjournal.com/article/S1098-3015(17)31237-8/fulltext
Title :
Health Care Resource Use (HCRU) Due To Bleeding Related Episodes (BRE) In Patients With Immune Thrombocytopenic Purpura (ITP) Receiving Eltrombopag (EPAG), Romiplostim (ROMI), Or Rituximab (RITUX)- Real World Evidence (RWE) From 27 US Insti ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31237-8&doi=10.1016/j.jval.2017.08.903
First page :
A558
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
866